Palmitoleic acid is an omega-7 monounsaturated fatty acid found more often in fixed oils and skin-lipid discussions than in classic volatile essential-oil perfumery. The strongest evidence supports its chemical identity, its occurrence at low levels in some carrier oils in the archive, and a preclinical literature around inflammation, macrophage signaling, and wound-healing models. Human evidence exists but is mixed: one 2023 placebo-controlled study reported improved skin-barrier measures, while a 2025 placebo-controlled trial did not reduce hs-CRP or other metabolic biomarkers, so copy should stay cautious and non-medical.
Chemical identity and composition
PubChem identifies palmitoleic acid as CID 445638 with formula C16H30O2 and IUPAC name (Z)-hexadec-9-enoic acid. ChEBI describes it as the cis-configured 9-unsaturated hexadecenoic acid and notes roles as a human blood serum metabolite and broader biological metabolite. In the archive it is currently a minor fatty-acid component in fixed oils such as cacay seed oil at 0.2% and plum kernel oil at 1.2%, which supports carrier-oil relevance more strongly than volatile-oil relevance.
Aroma and practical use
- Use the recorded fatty, oily, waxy, faint descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2017 macrophage study found that palmitoleic acid reduced inflammatory markers including NFkB-related signaling and lowered IL-6 or TNF-alpha outputs in LPS-stimulated primary macrophages, with the authors concluding the anti-inflammatory effect was independent of PPAR-alpha, PPAR-gamma, and AMPK.
A 2017 macrophage study found that palmitoleic acid reduced inflammatory markers including NFkB-related signaling and lowered IL-6 or TNF-alpha outputs in LPS-stimulated primary macrophages, with the authors concluding the anti-inflammatory effect was independent of PPAR-alpha, PPAR-gamma, and AMPK.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 rat wound model reported that topical palmitoleic acid hastened wound closure, reduced LPS-induced TNF-alpha, IL-1beta, IL-6, MIP-3alpha, and l-selectin release, and inhibited neutrophil migration.
A 2018 rat wound model reported that topical palmitoleic acid hastened wound closure, reduced LPS-induced TNF-alpha, IL-1beta, IL-6, MIP-3alpha, and l-selectin release, and inhibited neutrophil migration.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 mouse study reported that palmitoleic acid reduced high-fat-diet-induced liver inflammation, lowered inflammatory cytokines and TLR4 content, and promoted M2a macrophage polarization independently of myeloid-cell PPAR-gamma.
A 2020 mouse study reported that palmitoleic acid reduced high-fat-diet-induced liver inflammation, lowered inflammatory cytokines and TLR4 content, and promoted M2a macrophage polarization independently of myeloid-cell PPAR-gamma.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 randomized double-blind placebo-controlled study in 90 healthy adults reported significant improvement in skin hydration and transepidermal water loss after 12 weeks of 500 mg/day palmitoleic acid, while wrinkle and elasticity measures did not significantly improve versus control.
A 2023 randomized double-blind placebo-controlled study in 90 healthy adults reported significant improvement in skin hydration and transepidermal water loss after 12 weeks of 500 mg/day palmitoleic acid, while wrinkle and elasticity measures did not significantly improve versus control.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2025 randomized placebo-controlled trial found that 500 mg/day or 1000 mg/day palmitoleic acid for 12 weeks did not significantly lower hs-CRP or change the other measured inflammatory or metabolic biomarkers versus placebo.
A 2025 randomized placebo-controlled trial found that 500 mg/day or 1000 mg/day palmitoleic acid for 12 weeks did not significantly lower hs-CRP or change the other measured inflammatory or metabolic biomarkers versus placebo.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Within the archive's fixed-oil records, palmitoleic acid is currently documented at 0.2% in cacay seed oil and 1.2% in plum kernel oil, supporting occurrence claims without overstating abundance.
Within the archive's fixed-oil records, palmitoleic acid is currently documented at 0.2% in cacay seed oil and 1.2% in plum kernel oil, supporting occurrence claims without overstating abundance.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe 2023 oral supplementation study explicitly evaluated safety over 12 weeks and did not report major safety concerns in the published abstract, but that does not substitute for broad constituent-specific toxicology across use routes.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
One older positive lipid-and-hs-CRP palmitoleic-acid trial indexed in PubMed was later marked as a retracted article, so it should not be used as reliable support for efficacy claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No fragrance-industry dermal limit or dedicated isolated-constituent inhalation safety monograph was verified in this pass for palmitoleic acid.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
nfkb pathway suppression in macrophages
In LPS-stimulated primary macrophages, palmitoleic acid reduced NFkB-related inflammatory markers and lowered cytokine outputs, supporting an anti-inflammatory signaling effect in cell models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
m2a macrophage polarization
A mouse high-fat-diet study reported reduced liver inflammation together with increased CD206-positive M2a macrophage polarization, suggesting an immunometabolic mechanism beyond simple lipid replacement.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
wound site cytokine modulation
Topical palmitoleic acid altered wound-site cytokine and chemokine profiles and reduced neutrophil migration in rat models, which offers a plausible mechanism for faster wound closure in that preclinical setting.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Human intervention evidence remains mixed and limited relative to the much larger preclinical literature.
- Most palmitoleic-acid activity data come from oral, metabolic, or cell-model research rather than inhalation or fragrance-use contexts.
- A dedicated fragrance-safety or dermal-limit monograph for isolated palmitoleic acid was not verified in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.